ABBV · News · 20260828N

Product Launch and Transition

AbbVie Inc. · 2026-08-28 · Importance 31 · Surprise 42

AbbVie is seeking European Union approval for a subcutaneous induction option of Skyrizi in Crohn’s disease. The formulation could provide patients with a more convenient administration option than the existing treatment pathway. Approval would expand Skyrizi’s positioning and potential use within AbbVie’s immunology portfolio in the EU Crohn’s disease market.

Key facts

• Beverly Hills Private Wealth LLC lowered its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 50.6% during the undefined quarter, owning 6,164 shares after selling 6,310 shares during the period. source